1. Effect of vaccination on pneumococci isolated from the nasopharynx of healthy children and the middle ear of children with otitis media in Iceland
- Author
-
Samuel Sigurdsson, Helga Erlendsdóttir, Angela B. Brueggemann, Andries J. van Tonder, Gunnsteinn Haraldsson, Ásgeir Haraldsson, Martha Á. Hjálmarsdóttir, Stephen D. Bentley, Karl G. Kristinsson, Birgir Hrafnkelsson, Sigríður Júlía Quirk, Læknadeild (HÍ), Faculty of Medicine (UI), Lífvísindasetur (HÍ), Biomedical Center (UI), Raunvísindadeild (HÍ), Faculty of Physical Sciences (UI), Heilbrigðisvísindasvið (HÍ), School of Health Sciences (UI), Verkfræði- og náttúruvísindasvið (HÍ), School of Engineering and Natural Sciences (UI), Háskóli Íslands, University of Iceland, Wellcome Trust, GlaxoSmithKline, and John Fell Fund, University of Oxford
- Subjects
0301 basic medicine ,Serotype ,Eyrnabólga ,Epidemiology ,Iceland ,HAEMOPHILUS-INFLUENZAE ,medicine.disease_cause ,molecular epidemiology ,DISEASE ,Pneumococcal Vaccines ,EMERGENCE ,Streptococcus pneurnoniae ,Drug Resistance, Multiple, Bacterial ,Nasopharynx ,vaccine ,STREPTOCOCCUS-PNEUMONIAE SEROTYPES ,EPIDEMIOLOGY ,Pneumókokkar ,Child ,education.field_of_study ,PENICILLIN-RESISTANT PNEUMOCOCCI ,Vaccination ,11 Medical And Health Sciences ,Pneumococcus ,Anti-Bacterial Agents ,3. Good health ,PCR ,Streptococcus pneumoniae ,Child, Preschool ,Molecular epidemiology ,Carrier State ,medicine.symptom ,Life Sciences & Biomedicine ,pneumococcus ,CONJUGATE VACCINE ,Microbiology (medical) ,030106 microbiology ,Population ,Ear, Middle ,UNITED-STATES ,Microbial Sensitivity Tests ,Serogroup ,complex mixtures ,Microbiology ,Pneumococcal Infections ,03 medical and health sciences ,stomatognathic system ,otorhinolaryngologic diseases ,medicine ,Humans ,Serotyping ,education ,Otitis media ,carriage ,Carriage ,Science & Technology ,business.industry ,Faraldsfræði ,Infant, Newborn ,Infant ,otitis media ,06 Biological Sciences ,Bóluefni ,vaccination ,Bólusetningar ,Multiple drug resistance ,Otitis ,07 Agricultural And Veterinary Sciences ,business ,Vaccine ,Genome, Bacterial ,Multilocus Sequence Typing - Abstract
Publisher's version (útgefin grein), Vaccination with pneumococcal conjugate vaccines (PCVs) disrupts the pneumococcal population. Our aim was to determine the impact of the 10-valent PCV on the serotypes, genetic lineages, and antimicrobial susceptibility of pneumococci isolated from children in Iceland. Pneumococci were collected between 2009 and 2017 from the nasopharynges of healthy children attending 15 day care centers and from the middle ears (MEs) of children with acute otitis media from the greater Reykjavik capital area. Isolates were serotyped and tested for antimicrobial susceptibility. Whole-genome sequencing (WGS) was performed on alternate isolates from 2009 to 2014, and serotypes and multilocus sequence types (STs) were extracted from the WGS data. Two study periods were defined: 2009 to 2011 (PreVac) and 2012 to 2017 (PostVac). The overall nasopharyngeal carriage rate was similar between the two periods (67.3% PreVac and 61.5% PostVac, P = 0.090). Vaccine-type (VT) pneumococci decreased and nonvaccine-type (NVT) pneumococci (serotypes 6C, 15A, 15B/C, 21, 22F, 23A, 23B, 35F, and 35B) significantly increased in different age strata post-PCV introduction. The total number of pneumococci recovered from ME samples significantly decreased as did the proportion that were VTs, although NVT pneumococci (6C, 15B/C, 23A, and 23B) increased significantly. Most serotype 6C pneumococci were multidrug resistant (MDR). Serotype 19F was the predominant serotype associated with MEs, and it significantly decreased post-PCV introduction: these isolates were predominantly MDR and of the Taiwan19F-14 PMEN lineage. Overall, the nasopharyngeal carriage rate remained constant and the number of ME-associated pneumococci decreased significantly post-PCV introduction; however, there was a concomitant and statistically significant shift from VTs to NVTs in both collections of pneumococci., This was an investigator-initiated study funded by GlaxoSmithKline Biologicals SA. Grants were received from the Landspitali University Hospital Research Fund, the Eimskip University Fund, the Wellcome Trust (research fellowship 083511/Z/07/Z and grant 04992/Z/14/Z to A.B.B.), and the John Fell Fund (grant 123/734 to A.B.B.). Work at the Wellcome Sanger Institute was supported by the Wellcome core funding (grant 206194 to S.D.B.)
- Published
- 2018